Patients with unrealistic expectations or diffuse weight-loss goals may not be suitable for localized contouring treatment
You might be doing everything you are supposed to do
We hypothesise that the absence of glucagon leads to improved oral glucose tolerance similar to that seen in glucagon receptor knockout mice, which also have minimal glucose excursions after an oral glucose load
Therapeutic Prospects BPC-157 is more stable than endogenous BPC and exhibits therapeutic properties without the need for a carrier agent
There is no specific guidance now the shortages have been resolved, but it is still recommended that GLP-1 RAs are only prescribed for their licensed indication
The evidence includes STEP (semaglutide, The New England Journal of Medicine , 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (NEJM 2024)